NCT06379217 2026-03-11
NEPC Study: An Exploratory Safety and Efficacy Study With PSMA, SSTR2 and GRPR Targeted Radioligand Therapy in Metastatic Neuroendocrine Prostate Cancer.
Novartis
Phase 1 Active not recruiting
Clinical Trials
9 trialsNCT05849298 2026-03-03
PSMACare
Novartis
Phase 2 Active not recruiting
NCT05413850 2026-03-02
Anti-tumour Activity of (177Lu) rhPSMA-10.1 Injection
Blue Earth Therapeutics Ltd
Phase 1/2 Recruiting
NCT05939414 2026-02-24
PSMA-DC
Novartis
Phase 3 Recruiting
NCT06894511 2026-02-17
PSMAndARPI
Novartis
Phase 2 Active not recruiting
NCT05701007 2026-01-29
Real World Evidence Study on Metastatic Prostate Cancer in the Pirkanmaa Hospital District in Finland
Pfizer
Completed
NCT06531499 2025-12-31
RADIODOSE
Novartis
Phase 1 Recruiting
NCT06517719 2025-12-30
Real-world Experience With Lutetium Vipivotide Tetraxetan in Metastatic Castration Resistant Prostate Cancer
Novartis
Recruiting
NCT06881823 2025-12-29
NeoPSMA
Novartis
Phase 1/2 Withdrawn